Treatment of patients with the latent form of papilloma virus infection
The examination embraced 63 patients with the latent form of papilloma virus infection (PVI). The antiviral immunomodulating drug Ferrovir was administered as the main therapeutic means. A single dose of the drug was 5.0 ml of 1.5% solution. The course of treatment consisted of 10 injections given every 72 hours. The efficacy of the therapy was assessed by the colposcopic and cytological pictures, PCR studies of cell substrates for presence/absence of human papilloma virus (HPV-16/18 types) and by correction of the indices of the immune system within 2 weeks, 3, 6 and 12 months after the termination of therapy. The use of Ferrovir resulted in correction of immunological indices in 100% of cases in the group of patients with newly diagnosed PVI and in 93.8% of cases in patients who previously received therapy. The elimination of HPV was noted in 100% of patients with newly diagnosed PVI and in 77.5% of patients who received treatment within the preceding 3 years. In previously untreated patients stably high immunological indices and negative results of PCR testing were observed 12 months after the course of therapy in 96.8 and 93.5% of cases, respectively,- and in patients with a history of PVI – in 78.1 and 78.1% of observations, respectively.